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ABSTRACT
The acute toxicity of organophosphates is usually attributed to their irreversible inhibition
of an enzyme acetylcholinesterase that hydrolyses the neurotransmitter acetylcholine. The
resultant increase in concentration of acetylcholine at the cholinergic synapses of the peripheral
and central nervous system, and neuromuscular junction is manifested by over-stimulation of
the cholinergic neurotransmission. Current antidotal regimens for organophosphate poisoning
consisting of a post-exposure therapy with anticholinergics such as atropine, acetylcholinesterase
reactivators (oximes), benzodiazepines have some limitations. Therefore, effective prophylaxis
before intoxication is of a special interest. Four fundamental prophylactic methods are: (i)
protection of acetylcholinesterase against irreversible inhibition by organophosphates using
different reversible inhibitors, (ii) protection against neurotoxic effect of organophosphates using
benzodiazepines, memantine,  NMDA receptor blockers, (iii) administration of cholinesterase
preparations of different sources (sometimes commercially available at present) acting as
bioscavengers, and (iv) gene therapy being a new treatment modality under intensive research
using enzymes hydrolysing/splitting organophosphates with the aim to eliminate toxic agent
before it is transported  to the target organs.
Keywords: Cholinesterases, inhibitors, organophosphates, poisoning, prophylaxis, pretreatment,
acetylcholinesterase, nerve agents, bioscavengers, gene therapy
1 . INTRODUCTION
Organophosphates (OPs) are widely used as
pesticides and have thus become environmental
contaminants. In addition, some OPs like sarin,
soman, VX and tabun are important chemical warfare
agents1. Their production and testing have been
forbidden by the international agreements2. Nerve
agents are rapidly acting chemicals that can cause
respiratory arrest within minutes after their absorption.
Their speed of action imposes a need for rapid and
appropriate reaction by exposed soldiers, their buddies
or medics, who must administer antidotes quickly
enough to save their lives.
The acute toxicity of OPs in mammals is primarily
due to their irreversible inhibition of acetylcholinesterase
(AChE; EC 3.1.1.7) in the nervous system, which
leads to increased synaptic acetylcholine levels.
However, the toxic effect of some OPs is not
limited to cholinesterase inhibition only. Following
cholinergic crisis, changes in noncholinergic parameters
such as specific damage of cell membranes are
observed3,4.  In the treatment of OPs poisoning, the
combination of anticholinergics like atropine and
some AChE reactivators called oximes (obidoxime,
pralidoxime, HI-6, etc.) has been used5-8. For the
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etc.) are administered8. However, the efficiency of
oximes is not satisfactory in the case of soman
poisoning, due to the rapid dealkylation (ageing) of
AChE. The resulting methylphosphonyl AChE is
resistant to the nucleophilic attack of oximes9,10.
Ageing renders oxime therapy much less effective
and poses a specially difficult problem for the treatment
of soman poisoning. It was found that pretreatment
with certain reversible inhibitors of cholinesterase
such as carbamates in conjunction with atropine
and oximes gave appreciable protection against
poisonings by many OPs, including soman11,12. A
number of possibilities exist to protect an organism
against organophosphate intoxication which are
summarised in this paper.
2 . PROTECTION POSSIBILITIES
Medical protection against nerve agents that
depends completely on post-exposure antidote treatment
has some limitations. Because of these limitations
of post-exposure protection, military physicians have
focused on the possibility of protecting soldiers
from nerve agents by medical prophylaxis designed
to limit the toxicity of a subsequent nerve agent
exposure. The administration of prophylactic antidote
is not so simple and has some difficulties13. The
pharmacological pretreatments that protect human
beings from the toxic effects of nerve agents are
themselves neuroactive compounds. A pretreatment
must be administered to the entire force under a
nerve agent threat. Any adverse interference of
soldier is unacceptable in battlefield situations requiring
maximum alertness and performance for survival.
Nowadays, four fundamental methods for protection
of the organisms against toxic OPs exist. These
are:
• Protection of acetylcholinesterase (AChE) against
irreversible inhibition by OP using suitable reversible
inhibitor
• Protection of neurons against OP induced
neurotoxicity using suitable drugs
• Displacement of OP using suitable bioscavenger
• Gene therapy to prevent OP intoxication by
increasing the specific hydrolytic activity of
PON1 paraoxonase/arylesterase enzymes in
liver and blood. These enzymes provide a natural
barrier against the entry of these agents into
the central and peripheral nervous systems, ie,
to the target sites of OPs toxic action.
2.1 Reversible Inhibitors of AChE
The prophylaxis against nerve agents is based
on the protection of AChE against irreversible inhibition
by OPs. Partial inhibition of AChE by some reversible
inhibitors protects the enzyme against irreversible
inhibition by OPs and, therefore, against the lethal
effects of organophosphorous nerve agents.
The possibility to protect AChE against irreversible
OP by the pretreatment of reversible inhibitor has
been known for many years14,15
. Several reversible
inhibitors were tested, for example mono-and bis-
pyridinium salts16, ketamine17,18, tacrine
(9-amino-1,2,3,4-terahydroacridine)19,20, huperzine
A 21,22 and others. However, the best results were
obtained using carbamates, viz., physostigmine and
pyridostigmine23-27. Physostigmine, a natural alkaloid
from the West African shrub Physostigma venenosum
is prophylactically active. Physostigmine penetrates
through the blood-brain barrier and therefore is
more efective than pyridostigmine in protecting
against the detrimental effects of soman28. However,
physostigmine is more toxic than pyridostigmine
and the difference between its therapeutic and
toxic dose is very narrow. In addition, its inhibition
effect on AChE is short lived. Since pyridostigmine
does not penetrate into the brain, it does not afford
protection against centrally initiated seizures and
subsequent neuropathology induced by an OP agent
such as soman. Nevertheless, pyridostigmine was
the first reversible inhibitor of AChE which was
used on human being as prophylactic antidote against
nerve agents.
Recommended dose of pyridostigmine
(pyridostigmine bromide29,30) as prophylactic antidote
is  30 mg every 8 h. At this recommended dose,
pyridostigmine did not show the side effects in
the animal efficacy studies conducted in several
species in a number of countries. Also, the evidence
of pyridostigmine pretreatment strongly enhancing
post-exposure antidote therapy for soman poisoning31,32
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was found. This approach shows the strongest
benefit of pyridostigmine pretreatment in comparison
with atropine and oxime therapy alone in animals
challenged with nerve agents33-37.
As an inhibitor of AChE, pyridostigmine in
large doses mimics the peripheral toxic effects of
nerve agents and therefore it might seem paradoxical
that carbamate compounds help in protection against
nerve agent poisoning. However, two critical
characteristics of the carbamate-enzyme bond explain
the usefulness of the carbamates: First, carbamoylation,
the interaction between the carbamates and the
active site of AChE, is reversible, unlike the normally
irreversible inhibition of AChE by the nerve agents.
No reactivators are needed to dissociate or
decarbamoylate the enzyme from a carbamate
compound. Carbamates do not undergo the ageing
reaction like nerve agents. Second, carbamoylated
AChE is resistant to inhibition by nerve agents
because the active site of the carbamoylated enzyme
is not accessible for binding of nerve agent molecules.
Functionally, sufficient excess AChE activity is
normally present in synapses so that carbamoylation
of 20 per cent to 40 per cent of the enzyme with
pyridostigmine does not significantly impair cholinergic
neurotransmission. When animals are challenged
with a lethal dose of nerve agent, AChE activity
normally decreases rapidly, becoming too low to
be measured. In pyridostigmine pretreated animals
with a sufficient quantity of carbamoylated enzyme,
spontaneous decarbamoylation of the enzyme
regenerates enough AChE activity to sustain vital
functions such as neuromuscular transmission to
support respiration. Pyridostigmine pretreatment
provides improved protection against OP exposure.
However, therapeutic effect is better when combined
with post-exposure antidote therapy. Prompt post-
exposure administration of atropine or other suitable
anticholinergic is still needed to antagonise acetylcholine
excess, and an oxime reactivator has also to be
administered if an excess of nerve agent remains
to attack the newly uncovered AChE active sites
that were protected by pyridostigmine34,38-40.
It appears from these results that with a higher
dose of pyridostigmine, a higher prophylactic efficacy
against nerve agents was observed, but some adverse
effects were also expressed. This problem was
solved by adding the anticholinergic drugs. This
prophylactic combination of pyridostigmine with
trihexyphenidyle and benactyzine called PANPAL
was developed and introduced into the Czech Armed
Forces. This antidote has better prophylactic efficacy
in comparison with pyridostigmine alone41-43
.
Nowadays, binary antidotes against OP poisoning
have been developed, because the combination of
pyridostigmine with a proper anticholinergic agent
are more effective and their undesirable effects
are suppressed.
It is very important because chronic pyridostigmine
administration is able due to these adverse reactions
and it is impossible to remove their concern in
health problem of Gulf war veterans44. It is known
that Gulf war veterans began to complain of symptoms
such as aching joints, chronic fatigue, memory
and concentration loss, headache, depression, anxiety,
gastrointestinal disturbances, problems in breathing,
frequent coughing, chest and heart pain, hives and
chemical sensitivities, eye and vision problems45.
This collection of symptoms acquired its name as
Gulf war illness (GWI) or Gulf war syndrome (GWS).
The toxicity of pyridostigmine is the result of
several different characteristics of the compound.
Inhibition of cholinesterase causes acetylcholine
to have a prolonged effect, leading to overactivation
of the parasympathetic pathway. This type of
overactivation results in respiratory and muscular
problems, as well as salivation, lacrimation, urination,
diaphoresis, gastroenteritic cramping, and emesis.
A pyridostigmine dose (above 2 mg/kg) was found
to be toxic in an experiment carried out on beagle
dogs, whose symptoms were gastrointestinal problems,
emesis, diarrhea, reddening of the stools, and death
caused by intestinal intusseception46. These symptoms,
though extreme, can be seen in a more mild form
in Gulf war veterans, who experience diarrhoea,
nausea, and stomach pain. High chronic toxicity
of pyridostigmine is one of the reasons why new
and safer prophylactic antidotes are sought47.
2.2 Neuroprotective Substances
Soman inhibited AChE is very difficult to reactivate
especially following poisoning with multiple lethal
doses of soman. In addition, the soman-AChE complex
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ages very rapidly, making it resistant to reactivation
and does not undergo spontaneous reactivation.
Also, convulsive activity in soman intoxication creates
a problem that has been linked to irreversible brain
damage. Therefore, prophylactic efficacies of
anticonvulsants were studied. The benzodiazepines
(diazepam, midazolam, alprazolam, triazolam,
clonazepam) were studied, but isolated prophylactic
administrations have not produced very good
effects4,48,49. Some experiments have shown that
memantine (1-amino-3,5-dimethyl adamantine)
prophylaxis potentiates the therapeutic activity of
standard antidotes used in OP intoxications50-54.
Memantine, a drug is used for the therapy of parkinson’s
disease, spasticity and other brain disorders, and
significantly protected hippocampal and cortical neurons
in culture against glutamate and N-methyl-D-aspartate
(NMDA) excitotoxicity54. In rats a single dose of
memantine (18 mg/kg) administered 1 h prior to a
subcutaneous injection of a 0.9 LD50 dose of soman
reduced the severity of convulsions and increased
survival. Survival, however, was accompanied by
neuronal loss in the frontal cortex, piriform cortex,
and hippocampus53,54.
Other NMDA receptor ion-channel blocker,
which was tested as prophylactic antidote against
OP poisoning, is dizocilpine (MK-801). Its prophylactic
effect is not quite clear. Dizocilpine is a neuroprotective
agent like memantine, which is a reversible AChE
inhibitor. The (-) form of dizocilpine, pharmacologically
less active enantiomer, was the most potent of the
two isomers as an AChE inhibitor (Ki for electric
eel and rat brain AChE being 6.2 m and 17.9
m, respectively, compared with 200 m and 450
m, respectively of the (+) form). Both enantiomers
premixed with AChE preparations, dose dependently
protected the enzyme from inactivation by
diisopropylfluorophosphate (DFP)55.
2.3 Bioscavengers
Another possibility to protect the organisms
from the OP toxic effects is the use of scavengers
that are able to bind organophosporus compounds.
Such suitable bioscavengers are enzymes that are
irreversibly inhibited by OPs or are able to hydrolyse
OPs. These diminish the level of OP absorbed in
the blood. Thus, the concentration of OP attainable
at the toxic target sites (peripheral and central
nervous system) is significantly decreased. Among
all the tested enzymes that were promising candidates
as scavengers of highly toxic nerve agents, significant
advances were achieved using cholinesterases56
.
Exogenous administration of plasma-derived
cholinesterases of both rodent and non-human primate
models have been successfully used as a safe and
efficacious prophylactic treatment to prevent poisoning
by OP compounds 57. A theoretical model for the
protection against organophosporus poisoning has
been developed and verified on seven OPs58. AChE
or BuChE has been considered as acceptable
bioscavengers 59-61. Moreover, pretreatment with
butyrylcholinesterase also showed protective effects
on AChE inhibition in the brain parts following
low-level sarin inhalation exposure62.
It has been demonstrated that cholinesterases
are an effective mode of pretreatment to prevent
OP toxicity in different animals. The efficacy of
cholinesterases as a bioscavenger of OP can be
enhanced by combining enzyme pretreatment with
oxime reactivation, since the scavenging capacity
extends beyond a stochiometric ratio (1:1) of ChE
to OP. Human BuChE (HBuChE) has previously
been shown to protect mice, rats, and monkeys
against multiple lethal toxic doses of organophosphorus
anticholinesterases63.
Enzyme therapy for the prevention and treatment
of poisoning depends on the availability of large
amounts of cholinesterases. Of the ChEs evaluated
so far, human serum butyrylcholinesterase (HBuChE)
has the maximum advantage as a potential candidate
for human use. A dose of HBuChE i.v. (200 mg)
is envisioned as a prophylactic treatment in human
beings that can be protected from exposure of up
to 2 lethal doses (LD50) of soman. A large-scale
purification of HBuChE from human plasma has
been developed64. The long-term stability of enzyme
obtained by this way was very good but the amount
of BuChE in human plasma is very low and its
preparation is complicated and costing. Better results
offer modern biotechnology methods. Transgenic
plants are being evaluated for their efficiency and
cost-effectiveness as a system for the bioproduction
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of therapeutically valuable proteins65. Production
of a recombinant isoform of human acetylcholinesterase
in transgenic tomato plants has been reported. An
active and stable acetylcholinesterase, which retains
the kinetic characteristics of the human enzyme.
High levels of specific activity were registered in
leaves (up to 25 nmol min-1 mg protein-1) and
fruits (up to 250 nmol min-1mg protein-1). Another
suitable source of cholinesterases is transgenic
animal. Protexia™ is  a recombinant version of
human butyrylcholinesterase from the milk of transgenic
goats, developed by Nexia Biotechnologies, Canada
(http://www.nexiabiotech.com).
Enzymes hydrolysing OP are  present in the
organism at physiological conditions. Generally, these
enzymes are able to hydrolyse G agents (sarin,
soman, etc.) more rapidly than V agents (VX and
derivatives). Some of these enzymes were purified
to obtain higher hydrolysing activity and  to detoxify
nerve agents. The connection between  the two
types of enzymes (cholinesterases and OP hydrolysing
enzymes) will be possible with aim of obtaining a
modified enzyme splitting OP and simultaneously
reacting with cholinesterases8,66.
2.4 Gene Therapy
The specific hydrolytic activity of PON1
paraoxonase/arylesterase enzymes in liver and blood
provides a natural barrier against the entry of
OPs into the central and peripheral nervous systems.
Inherited differences in the concentrations of PON1
enzyme may determine the extent of susceptibility
to OP injury in human beings. The findings of
Cowan, et al. indicate that boosting serum levels
of PON1 enzymes by a gene delivery vector raises
the threshold for OP toxicity by hydrolytic destruction
before the chemical can enter the brain67. Gene
therapy to prevent OP intoxication is a probability
for the future. Another possibility for the neutralisation
of OP in the body are monoclonal antibodies, that
have proper characteristics for use as an
immunocytochemical reagent of high specificity68,69.
3 . CONCLUSION
At present prophylaxis against nerve agent
toxicity makes the use of the reversible binding
of carbamate cholinesterase inhibitors such as
pyridostigmine to AChE. While the AChE is bound
to pyridostigmine, enzyme is protected against the
irreversible attack by the nerve agents. Since only
a small amount of acetylcholinesterase is required
for normal nerve transmission, toxicity is prevented
by the constant release of active enzyme from its
binding with pyridostigmine. Better prophylactic
efficacy without adverse effects was achieved
using its combination with two anticholinergics
(PANPAL). These two prophylactic antidotes are
being used against nerve agent action for the military
purposes in the Czech Armed Forces, while the
other prophylactic antidotes like cholinesterase
bioscavengers and gene therapy, are still experimented
in the laboratories.
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